(Q33379271)

English

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

11

object named as

Julien Taieb

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Thierry Poynard

object named as

Thierry Poynard

8

0 references

author name string

Amani Asnacios

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Laetitia Fartoux

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Olivier Romano

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chloe Tesmoingt

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Samy Louafi S

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Touraj Mansoubakht

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pascal Artru

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Olivier Rosmorduc

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mohamed Hebbar

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

112

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2733-2739

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of transforming growth factor alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met and acidic fibroblast growth factor/fibroblast growth factor receptors during hepatocarcinogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23489

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23489

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33379271&oldid=1536527793"